Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129778 · ClinicalTrials.gov registry record · NA
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01129778: Clinical Trial NA study, sponsored by Stanford University.
NCT01129778 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01129778, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food and Drug Administration (FDA) for the treatment of GERD. The investigators hope to learn the effectiveness of Zegerid for reducing the amount of acid reflux patients are experiencing in the esophagus (swallowing pipe).
Primary Outcome
Reported as the the average percentage over 24 hours of total time, upright time, and supine time per day with pH \<4 (symptomatic acid state) as evaluated with the Bravo pH monitoring technique.
Interventions
- DRUG Zegerid (proton pump inhibitor)
- PROCEDURE Bravo pH monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-12 |
| Phase | NA |
Why NCT01129778 stopped before completion
NCT01129778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Zegerid (proton pump inhibitor) is the first listed.
NCT01129778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01129778 about?
NCT01129778 is a clinical study titled "Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus". The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food a...
What is the current status of trial NCT01129778?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2009-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01129778?
The interventions under investigation include: Zegerid (proton pump inhibitor) (DRUG), Bravo pH monitoring (PROCEDURE).
Who is sponsoring clinical trial NCT01129778?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01129778's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia